Sheridan Legacy Sells Diamondback Drugs to Tailwind
December 23, 2014
Sheridan Legacy Group has announced the sale of Diamondback Drugs, a veterinary compounding pharmacy, to Tailwind Capital. Serving veterinary clinics and hospitals as well as zoos, aquariums and individual pet owners, Diamondback provides pharmaceuticals ranging from ophthalmic preparations to cancer treatment solutions. Sheridan had backed the company since 2012.